# Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

> **NCT04301843** · PHASE2 · RECRUITING · sponsor: **Giselle Sholler** · enrollment: 131 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Eflornithine

## Key facts

- **NCT ID:** NCT04301843
- **Lead sponsor:** Giselle Sholler
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-25
- **Primary completion:** 2028-10-01
- **Final completion:** 2033-10-01
- **Target enrollment:** 131 (ESTIMATED)
- **Last updated:** 2026-02-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04301843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04301843, "Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04301843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*